Related Experiment Video
Updated: Jun 14, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
The Association of Lipoprotein(a) and Stroke Recurrence: A Systematic Review and Meta-Analysis
Lina Palaiodimou1, Konstantinos Melanis1, Maria-Ioanna Stefanou1,2,3
1Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Insights
Elevated Lipoprotein(a) [Lp(a)] levels increase the risk of stroke recurrence and poor functional outcomes in patients who have had an ischemic stroke. Lp(a) shows potential as a biomarker and therapeutic target for secondary stroke prevention.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Clinical Research
Background:
- Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular disease risk factor.
- Lp(a) is structurally similar to low-density lipoprotein.
- The role of Lp(a) in secondary stroke prevention, specifically stroke recurrence, is not well-defined.
Purpose of the Study:
- To investigate the association between Lp(a) levels and stroke recurrence.
- To evaluate Lp(a) as a predictor of functional outcomes post-stroke.
- To explore Lp(a)'s role in secondary prevention strategies for ischemic stroke.
Main Methods:
- Systematic search of MEDLINE and Scopus databases for relevant randomized controlled trials (RCTs) and observational studies.
- Inclusion criteria focused on patients with ischemic stroke or transient ischemic attack reporting Lp(a) levels.
- Primary outcome was stroke recurrence; secondary outcomes included functional outcome, mortality, and recurrent vascular events. Pooled odds ratios were calculated.
Main Results:
- Twelve studies (1 RCT analysis, 11 observational) with 17,903 patients were analyzed.
- Elevated Lp(a) levels significantly correlated with increased stroke recurrence (OR: 1.69) and poor functional outcome (OR: 2.09).
- No significant associations were found between Lp(a) and all-cause mortality or recurrent vascular events.
Conclusions:
- Elevated Lp(a) levels are associated with higher rates of stroke recurrence and worse functional outcomes in stroke patients.
- Lp(a) emerges as a potential novel therapeutic target for secondary stroke prevention.
- Lp(a) may serve as a valuable biomarker in managing stroke patients.
Background And Purpose:
Lipoprotein(a) [Lp(a)] is a lipoprotein structurally similar to low-density lipoprotein and is considered a genetically determined risk factor for cardiovascular disease. Although Lp(a) has been linked to ischemic stroke, its role in secondary stroke prevention, particularly in stroke recurrence, remains unclear.
Methods:
A systematic search of MEDLINE and Scopus databases was conducted to identify randomized controlled trials (RCTs) and observational studies reporting Lp(a) levels in patients with ischemic stroke or transient ischemic attack. The primary outcome was stroke recurrence, and secondary outcomes included poor functional outcome, all-cause mortality, and recurrent vascular events. Pooled odds ratios (ORs) were calculated using a random-effects model.
Results:
A total of 12 studies, including one RCT post hoc analysis and 11 observational studies, comprising 17,903 patients (mean age 63 years, 38% female), were included. Elevated Lp(a) levels were significantly associated with increased stroke recurrence (OR: 1.69; 95% confidence interval [CI]: 1.09-2.63; P=0.020) and poor functional outcome (OR: 2.09; 95% CI: 1.40-3.11; P<0.001). No significant associations were found between Lp(a) levels and all-cause mortality (OR: 2.20; 95% CI: 0.89-5.43; P=0.088) or recurrent vascular events (OR: 2.66; 95% CI: 0.95-7.44; P=0.063).
Conclusion:
Elevated Lp(a) levels are linked to increased stroke recurrence and poor functional outcome in stroke patients. Lp(a) may represent a novel therapeutic target in secondary stroke prevention in addition to a promising biomarker.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents